tumor mutational burden
Iovance Biotherapeutics Shares New TIL Data in Melanoma, Projects Lifileucel FDA Filing in August
Premium
Investors were unimpressed last week with the data they saw, though the company tried to reassure them that the findings were positive given the refractory population.
BostonGene Closes $150M Series B Funding Round
The firm will use the financing to further the development, clinical expansion, and international availability of its Tumor Portrait tests.
Illumina Obtains CE-IVD Marking for European Version of TSO Comprehensive Assay
The next-generation sequencing-based assay detects variants in 517 genes and genomic signatures using formalin-fixed, paraffin-embedded tumor tissue samples.
The company launched EpiSwitch CiRT in the US last month as a lab-developed test, which it hopes will be better than existing predictive immunotherapy biomarkers.
Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps
Amid new treatment options and a growing list of actionable biomarkers, the field last year also focused on the need to better support oncologists and address access gaps for patients.